CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
CAPRICOR THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.65−0.06 (-0.89%)
Close on Oct 19, 2026
- Market cap
- $385.21M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
67.6%
39M of 58M shares
Institutional holders
170
30 new, 35 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $8.37M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nippon Shinyaku Co., Ltd. | 7,090,351 | 18.90% | 13G (passive) amendment | Sep 20, 2024 |
| Kevin Tang | 4,099,900 | 7.10% | 13G (passive) amendment | Jun 30, 2026 |
| Aaron Cowen | 3,417,891 | 6.60% | 13G (passive) | Feb 19, 2026 |
| State Street Corporation | 3,397,241 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Rajeev Shah | 3,014,183 | 5.20% | 13G (passive) | Jul 27, 2026 |
| BlackRock, Inc. | 2,966,914 | 6.50% | 13G (passive) amendment | Dec 31, 2024 |
| Millennium Management LLC | 2,943,086 | 5.10% | 13G (passive) | Sep 8, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CAPR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,145,061 | 7.13% | $99.81M | +723,246 | 0.00% |
| Tang Capital Management LLC | 4,099,900 | 7.05% | $98.73M | +700,000 | 4.48% |
| Suvretta Capital Management, LLC | 4,092,784 | 7.04% | $98.55M | +274,184 | 1.80% |
| State Street Corp | 3,397,150 | 5.84% | $81.80M | +1,215,249 | 0.00% |
| Vanguard Capital Management LLC | 2,297,674 | 3.95% | $55.33M | +269,942 | 0.00% |
| Goldman Sachs Group Inc | 1,578,131 | 2.71% | $38.00M | +666,155 | 0.00% |
| Ra Capital Management, L.P. | 1,507,844 | 2.59% | $36.31M | – | 0.32% |
| Boxer Capital Management, LLC | 1,395,156 | 2.40% | $33.60M | +805,156 | 2.53% |
| Geode Capital Management, LLC | 1,372,286 | 2.36% | $33.05M | +253,960 | 0.00% |
| FMR LLC | 1,137,730 | 1.96% | $27.40M | +365,081 | 0.00% |
| Citadel Advisors LLC | 814,444 | 1.40% | $19.61M | +275,212 | 0.00% |
| Mercer Global Advisors Inc /Adv | 802,732 | 1.38% | $19.33M | +399,733 | 0.02% |
| Soleus Capital Management, L.P. | 761,737 | 1.31% | $18.34M | New | 0.63% |
| Morgan Stanley | 684,515 | 1.18% | $16.48M | +260,696 | 0.00% |
| Vanguard Portfolio Management LLC | 636,087 | 1.09% | $15.32M | +256,873 | 0.00% |
| UBS Group AG | 619,661 | 1.07% | $14.92M | +247,677 | 0.00% |
| DG Capital Management, LLC | 611,595 | 1.05% | $14.73M | +219,499 | 3.10% |
| Ikarian Capital, LLC | 604,215 | 1.04% | $14.55M | +76,200 | 1.57% |
| Northern Trust Corp | 503,532 | 0.87% | $12.13M | +85,989 | 0.00% |
| Balyasny Asset Management L.P. | 486,836 | 0.84% | $11.72M | +189,713 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 170 | 39M | 67.6% | 30 / 72 | 45 / 35 | 9M | 4M |
| Q1 2026 | 177 | 34M | 58.2% | 71 / 58 | 35 / 22 | 14M | 5M |
| Q4 2025 | 132 | 27M | 47.2% | 45 / 43 | 39 / 24 | 15M | 2M |
| Q3 2025 | 115 | 15M | 25.2% | 34 / 26 | 36 / 26 | 4M | 3M |
| Q2 2025 | 107 | 14M | 23.6% | 16 / 41 | 37 / 29 | 2M | 6M |
| Q1 2025 | 121 | 18M | 31.6% | 33 / 47 | 23 / 19 | 3M | 2M |
| Q4 2024 | 108 | 17M | 29.8% | 51 / 35 | 15 / 17 | 11M | 2M |
| Q3 2024 | 75 | 8M | 14.5% | 29 / 21 | 12 / 14 | 5M | 1M |
| Q2 2024 | 61 | 6M | 11.1% | 22 / 18 | 16 / 17 | 3M | 2M |
| Q1 2024 | 56 | 5M | 8.8% | 24 / 17 | 8 / 5 | 2M | 1M |
| Q4 2023 | 37 | 4M | 7.0% | 6 / 15 | 8 / 3 | 1M | 3M |
| Q3 2023 | 34 | 6M | 9.5% | 5 / 8 | 11 / 3 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CAPR | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,178,269 | 3.75% | $52.45M | 0.49% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,655,365 | 2.85% | $39.86M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,400,623 | 2.41% | $33.73M | 0.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 591,508 | 1.02% | $14.24M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 587,905 | 1.01% | $2.26M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 496,401 | 0.85% | $11.95M | 0.08% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 334,200 | 0.57% | $10.01M | 0.19% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 238,101 | 0.41% | $7.13M | 0.02% | May 31, 2026 |
| Select Pharmaceuticals Portfolio | 231,300 | 0.40% | $6.93M | 0.46% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 223,876 | 0.39% | $6.71M | 0.04% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 190,170 | 0.33% | $5.70M | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 130,634 | 0.22% | $502.94K | 0.01% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 110,633 | 0.19% | $425.94K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 100,532 | 0.17% | $2.42M | 0.04% | Jun 30, 2026 |
| Invesco Dorsey Wright SmallCap Momentum ETF | 87,370 | 0.15% | $2.62M | 0.63% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Linda Marban | CHIEF EXECUTIVE OFFICER, Director | 521,019 | 0.90% | Jan 7, 2026 |
| Karen Krasney | EVP, GENERAL COUNSEL | 30,547 | 0.05% | Jun 29, 2026 |
| Anthony Bergmann | CHIEF FINANCIAL OFFICER | 11,223 | 0.02% | Jun 29, 2026 |
| Michael T. Maurer | CHIEF COMMERCIAL OFFICER | – | – | May 28, 2026 |
| Frank Litvack | Director | 180,054 | 0.31% | May 14, 2026 |
| Karimah Es Sabar | Director | 7,529 | 0.01% | Apr 3, 2026 |
| George W. Dunbar Jr | Director | 14,306 | 0.02% | Jan 7, 2026 |
| David B. Musket | Director | 88,788 | 0.15% | Jan 7, 2026 |
| Philip J. Gotwals | Director | – | – | Jan 7, 2026 |
| Paul Gisbert Auwaerter | Director | 5,000 | 0.01% | Jan 7, 2026 |
| Mike Kelliher | Director | – | – | Jan 7, 2026 |
| Earl M. Collier Jr | Director | 57,606 | 0.10% | Feb 28, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Karen Krasney EVP, GENERAL COUNSEL | Jun 25, 2026 | Sale(10b5-1 plan) | −24,100 | $30.38 | $732.16K | 30,547 |
| Karen Krasney EVP, GENERAL COUNSEL | Jun 25, 2026 | Option exercise | +24,100 | $3.18 | $76.64K | 54,647 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Jun 25, 2026 | Sale(10b5-1 plan) | −24,100 | $30.38 | $732.16K | 11,223 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Jun 25, 2026 | Option exercise | +24,100 | $3.18 | $76.64K | 35,323 |
| Karen Krasney EVP, GENERAL COUNSEL | Jun 24, 2026 | Option exercise | +400 | $3.18 | $1.27K | 30,947 |
| Karen Krasney EVP, GENERAL COUNSEL | Jun 24, 2026 | Sale(10b5-1 plan) | −400 | $30.00 | $12.00K | 30,547 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Jun 24, 2026 | Sale(10b5-1 plan) | −400 | $30.00 | $12.00K | 11,223 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Jun 24, 2026 | Option exercise | +400 | $3.18 | $1.27K | 11,623 |
| Karen Krasney EVP, GENERAL COUNSEL | Jun 22, 2026 | Sale(10b5-1 plan) | −500 | $30.00 | $15.00K | 30,547 |
| Karen Krasney EVP, GENERAL COUNSEL | Jun 22, 2026 | Option exercise | +500 | $3.18 | $1.59K | 31,047 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Jun 22, 2026 | Sale(10b5-1 plan) | −500 | $30.00 | $15.00K | 11,223 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Jun 22, 2026 | Option exercise | +500 | $3.18 | $1.59K | 11,723 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | May 18, 2026 | Option exercise | +3,000 | $1.39 | $4.17K | 11,223 |
| Frank Litvack Director | May 13, 2026 | Option exercise | +3,937 | $1.39 | $5.47K | 133,776 |
| Karen Krasney EVP, GENERAL COUNSEL | May 1, 2026 | Option exercise | +25,000 | $3.18 | $79.50K | 55,547 |
| Karen Krasney EVP, GENERAL COUNSEL | May 1, 2026 | Sale(10b5-1 plan) | −25,000 | $31.70 | $792.50K | 30,547 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | May 1, 2026 | Sale(10b5-1 plan) | −25,000 | $31.70 | $792.50K | 8,223 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | May 1, 2026 | Option exercise | +25,000 | $3.18 | $79.50K | 33,223 |
| Karimah Es Sabar Director | Apr 2, 2026 | Option exercise | +7,529 | $3.18 | $23.94K | 7,529 |
| Karimah Es Sabar Director | Apr 2, 2026 | Sale(10b5-1 plan) | −7,529 | $32.00 | $240.93K | 0 |
| Karimah Es Sabar Director | Apr 1, 2026 | Sale(10b5-1 plan) | −53,735 | $31.03 | $1.67M | 0 |
| Karimah Es Sabar Director | Apr 1, 2026 | Option exercise | +53,735 | $4.86 | $261.15K | 53,735 |
| Karimah Es Sabar Director | Mar 31, 2026 | Sale(10b5-1 plan) | −61,265 | $30.17 | $1.85M | 0 |
| Karimah Es Sabar Director | Mar 31, 2026 | Option exercise | +61,265 | $4.86 | $297.75K | 61,265 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Mar 31, 2026 | Sale(10b5-1 plan) | −25,000 | $30.13 | $753.25K | 8,223 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Mar 31, 2026 | Option exercise | +25,000 | $3.18 | $79.50K | 33,223 |
| Karen Krasney EVP, GENERAL COUNSEL | Mar 31, 2026 | Option exercise | +21,488 | $3.74 | $80.37K | 52,728 |
| Karen Krasney EVP, GENERAL COUNSEL | Mar 31, 2026 | Sale(10b5-1 plan) | −25,000 | $30.12 | $753.00K | 30,547 |
| Karen Krasney EVP, GENERAL COUNSEL | Mar 31, 2026 | Option exercise | +693 | $1.39 | $963 | 31,240 |
| Karen Krasney EVP, GENERAL COUNSEL | Mar 31, 2026 | Option exercise | +2,819 | $3.18 | $8.96K | 55,547 |
| Karen Krasney EVP, GENERAL COUNSEL | Dec 30, 2025 | Option exercise | +2,500 | $1.39 | $3.47K | 30,547 |
| George W. Dunbar Jr Director | Dec 19, 2025 | Option exercise | +3,000 | $1.39 | $4.17K | 14,306 |
| Linda Marban CHIEF EXECUTIVE OFFICER, Director | Mar 5, 2025 | Other | −12,500 | – | – | 211,104 |
| Linda Marban CHIEF EXECUTIVE OFFICER, Director | Mar 3, 2025 | Option exercise | +25,000 | $1.39 | $34.75K | 223,604 |
| George W. Dunbar Jr Director | Mar 3, 2025 | Option exercise | +750 | $1.39 | $1.04K | 11,306 |
| Frank Litvack Director | Mar 3, 2025 | Option exercise | +25,000 | $1.39 | $34.75K | 132,382 |
| Frank Litvack Director | Mar 3, 2025 | Tax withholding | −2,543 | $13.67 | $34.76K | 129,839 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Mar 3, 2025 | Option exercise | +2,500 | $1.39 | $3.47K | 8,223 |
| Earl M. Collier Jr Director | Feb 27, 2025 | Option exercise | +750 | $1.39 | $1.04K | 57,606 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Jan 2, 2025 | Award | +3,342 | – | – | 5,723 |
| Karen Krasney EVP, GENERAL COUNSEL | Dec 13, 2024 | Option exercise | +8,000 | $1.39 | $11.12K | 28,047 |
| Frank Litvack Director | Dec 3, 2024 | Option exercise | +20,391 | $1.10 | $22.43K | 46,278 |
| Shinyaku Co Ltd Nippon 10% owner | Sep 20, 2024 | Buy | +2,798,507 | $5.36 | $15.00M | 7,090,351 |
| David B. Musket Director | Aug 7, 2024 | Option exercise | +34,000 | $1.39 | $47.26K | 81,692 |
| Earl M. Collier Jr Director | Apr 23, 2024 | Option exercise | +30,000 | $1.39 | $41.70K | 56,856 |
| David B. Musket Director | Apr 23, 2024 | Option exercise | +16,156 | $1.39 | $22.46K | 47,692 |
| Anthony Bergmann CHIEF FINANCIAL OFFICER | Oct 23, 2023 | Option exercise | +2,178 | $1.39 | $3.03K | 2,381 |
| David B. Musket Director | Oct 12, 2023 | Buy | +410 | $2.75 | $1.13K | 31,536 |
| Earl M. Collier Jr Director | Oct 10, 2023 | Buy | +10,000 | $2.83 | $28.30K | 26,856 |
| David B. Musket Director | Oct 9, 2023 | Buy | +5,083 | $2.82 | $14.33K | 31,126 |
| Paul Gisbert Auwaerter Director | Oct 6, 2023 | Buy | +5,000 | $2.84 | $14.20K | 5,000 |
| David B. Musket Director | Oct 4, 2023 | Buy | +2,500 | $2.90 | $7.25K | 26,043 |
| Frank Litvack Director | Aug 14, 2023 | Option exercise | +20,748 | $1.39 | $28.84K | 137,633 |
| Frank Litvack Director | Aug 14, 2023 | Tax withholding | −4,364 | $6.61 | $28.85K | 133,269 |
| Linda Marban CHIEF EXECUTIVE OFFICER, Director | May 12, 2023 | Option exercise | +20,749 | $1.39 | $28.84K | 198,604 |
| Xavier Avat – | Apr 17, 2023 | Sale | −14,772 | $64258.00 | $949.22M | 0 |
| Xavier Avat – | Apr 5, 2023 | Tax withholding | −70,019 | $4.19 | $293.38K | 14,772 |
| Xavier Avat – | Apr 5, 2023 | Option exercise | +84,791 | $3.46 | $293.38K | 84,791 |
| Xavier Avat – | Mar 28, 2023 | Sale | −3,000 | $4.06 | $12.18K | 0 |
| Louis Manzo Director | Feb 21, 2023 | Option exercise | +1,401 | $1.39 | $1.95K | 62,599 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David B. Musket Director | May 19, 2026 | 88,788 | $2.40M | May 19, 2026 | Purchase |
| David B. Musket Director | May 19, 2026 | 10,000 | $273.20K | May 19, 2026 | Stock Award |
| Es Sabar Karimah Director | Apr 2, 2026 | 7,529 | $226.77K | Apr 2, 2026 | Exercise of Stock Options |
| Krasney Karen Officer | Mar 31, 2026 | 75,000 | $2.08M | Mar 31, 2026 | Exercise of Stock Options |
| Bergmann Anthony Officer | Mar 31, 2026 | 75,000 | $2.08M | Mar 31, 2026 | Exercise of Stock Options |
| Es Sabar Karimah Director | Mar 31, 2026 | 115,000 | $3.19M | Mar 31, 2026 | Exercise of Stock Options |